Pricing Log in Create free account

Bright Minds Biosciences Inc. (DRUG) vs Palisade Bio, Inc. (PALI)

Bright Minds Biosciences Inc. and Palisade Bio, Inc. are both Biotechnology companies. Bright Minds Biosciences Inc. and Palisade Bio, Inc. are of similar size ($204.2M and $202.2M). Bright Minds Biosciences Inc. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 1.8×. Bright Minds Biosciences Inc. has the higher net margin (0.00% vs −4,230.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Bright Minds Biosciences Inc. leads on 8 and Palisade Bio, Inc. on 4.

Valuation

Metric DRUG PALI Biotechnology median
P/E n/m 1.76 10.60
P/S n/m 319.17 9.40
P/B 1.01 1.98 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 154.02 9.02
Earnings yield (9.09%) 56.81% (32.88%)
Free cash flow yield (7.89%) (7.55%) (23.13%)

Profitability

Metric DRUG PALI Biotechnology median
Gross margin 0.00% 95.63% 68.51%
Operating margin 0.00% (4,681.99%) 0.00%
Net margin 0.00% (4,230.60%) 0.00%
Free cash flow margin 0.00% (2,409.27%) 0.00%
Return on equity (13.64%) (51.37%) (51.96%)
Return on assets (13.52%) (47.68%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DRUG PALI Biotechnology median
Revenue growth (TTM) — 5,492.59% 6.76%
EPS growth (last fiscal year) (164.58%) 97.06% 29.88%
Revenue growth, 5-year CAGR — 72.86% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DRUG PALI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 121.98 24.26 4.97
Net debt to EBITDA 5.98 7.37 1.01

Dividend

Metric DRUG PALI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DRUG PALI Biotechnology median
Market cap 204.18m 202.16m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack